About donanemab
Amyloid-beta monoclonal antibody
Used for
- Treats early symptomatic Alzheimer’s disease, including mild cognitive impairment or mild dementia, with confirmed amyloid plaques.
Usual adult dose
700 mg by intravenous infusion every four weeks for three doses, then 1,400 mg every four weeks.
Common side effects
- Amyloid-related brain swelling or bleeding
- Infusion-related reactions
- Headache
- Nausea
Important warnings
- Brain swelling and bleeding can be serious or fatal; monitoring requires brain scans.
- Risk is higher in people with two APOE ε4 copies.
- Treatment is for early Alzheimer’s disease with confirmed amyloid plaques.
- Use caution with anticoagulants or medicines that affect clotting.
Pregnancy
There are no adequate human pregnancy data; potential fetal risk is uncertain.
Breastfeeding
It is unknown whether donanemab passes into human milk or affects a breastfed infant.
Interactions
- Anticoagulants and clot-affecting medicines may increase concern about brain bleeding.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.